Hormonal
Chronic sleep deficiency (defined as inadequate or mistimed sleep) acts as an independent etiological factor for cardiovascular disease, metabolic disorders (obesity, type 2 diabetes), and increased mortality, distinct from primary sleep disorders.
Prioritize getting 7-8 hours of sleep per night as a non-negotiable health pillar, equivalent to diet and exercise. Chronic sleep restriction (<7 hours) independently increases your risk for heart disease, diabetes, obesity, and early death through hormonal and inflammatory pathways. Addressing sleep deficiency is a high-impact, achievable behavior change for public health.
Sleep deprivation contributes to a number of molecular, immune, and neural changes that play a role in disease development, independent of primary sleep disorders. These changes in biological processes in response to chronic sleep deficiency may serve as etiological factors for the development and exacerbation of cardiovascular and metabolic diseases and, ultimately, a shortened lifespan.
Why this rating
Based on large epidemiological studies (CPS-II, NHANES) and consistent mechanistic findings, though human RCTs on mortality are ethically impossible.
Source
Sleep: A Health Imperative
Faith S. Luyster et al. · SLEEP · 2012
DOI 10.5665/sleep.1846
More from this paper
- Short sleep duration (≤6 hours/night) is associated with increased odds of obesity (1.5x) and type 2 diabetes, mediated by hormonal changes including reduced leptin, increased ghrelin, and elevated evening cortisol.Good
- Sleep deprivation impairs cognitive and motor performance to a degree comparable to alcohol intoxication at or above the legal limit, significantly increasing the risk of motor vehicle crashes and work-related injuries.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →